CY1115446T1 - Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης - Google Patents
Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξηςInfo
- Publication number
- CY1115446T1 CY1115446T1 CY20141100523T CY141100523T CY1115446T1 CY 1115446 T1 CY1115446 T1 CY 1115446T1 CY 20141100523 T CY20141100523 T CY 20141100523T CY 141100523 T CY141100523 T CY 141100523T CY 1115446 T1 CY1115446 T1 CY 1115446T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- allogenic cells
- operative infection
- allogeneic cells
- cells
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000001388 Opportunistic Infections Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4641—Fungal antigens, e.g. Trichophyton, Aspergillus or Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Μια μέθοδος για την διέγερση του ανοσιακού συστήματος σε ανοσοκατασταλμένους ασθενείς προκειμένου να υποβληθεί σε αγωγή η ευκαιριακή λοίμωξη. Η μέθοδος ενέχει την έγχυση εκ προθέσεως αναντίστοιχων αλλογενών κυττάρων. Προκειμένου να αποτραπούν οι επιπλοκές της πάθησης μοσχεύματος-έναντι-ξενιστή, τα αλλογενή κύτταρα μπορούν να ακτινοβοληθούν προ της έγχυσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06750196.5A EP2003978B1 (en) | 2006-04-13 | 2006-04-13 | Allogeneic cell therapy for treatment of opportunistic infection |
PCT/US2006/014088 WO2007120128A1 (en) | 2006-04-13 | 2006-04-13 | Allogeneic cell therapy for treatment of opportunistic infection |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115446T1 true CY1115446T1 (el) | 2017-01-04 |
Family
ID=38609793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100523T CY1115446T1 (el) | 2006-04-13 | 2014-07-11 | Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2003978B1 (el) |
JP (1) | JP5254952B2 (el) |
CA (1) | CA2649290C (el) |
CY (1) | CY1115446T1 (el) |
DK (1) | DK2003978T3 (el) |
ES (1) | ES2482141T3 (el) |
IL (1) | IL194667A (el) |
PL (1) | PL2003978T3 (el) |
PT (1) | PT2003978E (el) |
SI (1) | SI2003978T1 (el) |
WO (1) | WO2007120128A1 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
US20120128656A1 (en) | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
WO2011130249A2 (en) * | 2010-04-13 | 2011-10-20 | Immunovative Therapies, Ltd. | Methods and compositions for inhibition of treg cells |
CA2799516C (en) * | 2010-08-06 | 2016-01-05 | Canine-Lab.Inc. | Immunological function enhancing agent |
EP2704732B1 (en) | 2011-05-03 | 2020-03-04 | Immunovative Therapies, Ltd. | Induction of il-12 using immunotherapy |
TWI676481B (zh) * | 2012-05-02 | 2019-11-11 | 以色列商梵提夫免疫療法公司 | 使用免疫療法誘導il-12 |
CA2782942C (en) | 2012-07-12 | 2019-08-27 | Canadian Blood Services | Method for inducing immune tolerance using polymer-modified antigenic leukocytes |
DK3019176T3 (da) | 2013-07-12 | 2020-06-22 | Canadian Blood Services | Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf |
EP3166618B1 (en) | 2014-07-10 | 2021-01-13 | Canadian Blood Services | Combination therapy of a cellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156312A (en) * | 1993-06-23 | 2000-12-05 | Leskovar; Peter | Agents, affecting the hyperactivated immunological effector cells |
-
2006
- 2006-04-13 ES ES06750196.5T patent/ES2482141T3/es active Active
- 2006-04-13 PT PT67501965T patent/PT2003978E/pt unknown
- 2006-04-13 CA CA2649290A patent/CA2649290C/en active Active
- 2006-04-13 DK DK06750196.5T patent/DK2003978T3/da active
- 2006-04-13 PL PL06750196T patent/PL2003978T3/pl unknown
- 2006-04-13 JP JP2009505345A patent/JP5254952B2/ja active Active
- 2006-04-13 WO PCT/US2006/014088 patent/WO2007120128A1/en active Application Filing
- 2006-04-13 SI SI200631800T patent/SI2003978T1/sl unknown
- 2006-04-13 EP EP06750196.5A patent/EP2003978B1/en active Active
-
2008
- 2008-10-12 IL IL194667A patent/IL194667A/en active IP Right Grant
-
2014
- 2014-07-11 CY CY20141100523T patent/CY1115446T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK2003978T3 (da) | 2014-07-07 |
EP2003978A1 (en) | 2008-12-24 |
EP2003978A4 (en) | 2009-07-22 |
PL2003978T3 (pl) | 2014-12-31 |
CA2649290A1 (en) | 2007-10-25 |
JP5254952B2 (ja) | 2013-08-07 |
SI2003978T1 (sl) | 2014-11-28 |
EP2003978B1 (en) | 2014-06-11 |
IL194667A (en) | 2015-06-30 |
WO2007120128A1 (en) | 2007-10-25 |
PT2003978E (pt) | 2014-07-25 |
ES2482141T3 (es) | 2014-08-01 |
JP2009533430A (ja) | 2009-09-17 |
CA2649290C (en) | 2017-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115446T1 (el) | Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης | |
WO2011056688A3 (en) | Molecular profiling for personalized medicine | |
CY1120360T1 (el) | Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων, ή για την αναστολη της αγγειογενεσης ογκων | |
CY1116090T1 (el) | Μεθοδος για σχηματισμο γελης φιμπροϊνης μεταξης χρησιμοποιωντας κατεργασια υπερηχων | |
MX2011013452A (es) | Tratamiento de cancer basado en exosomas. | |
AR055038A1 (es) | Metodo y compuesto para tratar enfermedades vasculares perifericas | |
BRPI0606108A2 (pt) | processo de tratamento | |
CY1125948T1 (el) | Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου | |
DK2023918T3 (da) | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser | |
EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
ATE520007T1 (de) | Bildgebungsgeometrie | |
EA201001691A1 (ru) | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору | |
CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα | |
MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
UA110325C2 (en) | Medicinal carbohydrates for treating respiratory conditions | |
EP2579863A4 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS | |
MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
AR060897A1 (es) | Metodo de vacunacion de sujetos que reciben terapia de inmunomodulacion | |
RU2008129232A (ru) | Способ лечения туберкулеза легких у больных вич-инфекцией | |
RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
UA35013U (ru) | Способ лечения больных брюшным тифом с наличием вторичного иммунодефицита | |
RU2009142007A (ru) | Способ лечения вазомоторного ринита | |
MX2011005054A (es) | Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple. | |
RU2008130241A (ru) | Способ и средство для реабилитации детей с хроническими риносинуситами |